Simpson Thacher recently represented the initial purchasers in connection with an offering of Notes by Roche Holdings, Inc. (“Roche”). The offering consisted of a Rule 144A and Regulation S offering of U.S.$900,000,000 aggregate principal amount of 4.203% notes due 2029, U.S.$1,000,000,000 aggregate principal amount of 4.592% notes due 2034 and U.S.$600,000,000 aggregate principal amount of additional 5.218% notes due 2054 (together, the “Notes”). The offering closed on September 9, 2024.
The net proceeds from the issue of the Notes will be used for general corporate purposes, including, among others, mergers and acquisitions, refinancing of short-term debt and regular debt maturities, payments of dividends and for potential early redemptions or mandatory prepayment events. The Roche Group is one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.
The Simpson Thacher team included Mark Brod, John C. Strubing and Sebastian Edin (Capital Markets); Vanessa Burrows and Jacob Madden (Healthcare); Michael Isby (Environmental); Bobbie Burrows and Siak Goh (IP/Data Privacy); and Jonathan Cantor and Michael Leitner (Tax).